IMGT CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,460 KRW | +3.57% |
|
-21.54% | +50.30% |
| 1 week | -21.54% | ||
| Current month | -21.54% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| 1 day | +3.57% | ||
| 1 week | -21.54% | ||
| Current month | -21.54% | ||
| 1 month | -43.62% | ||
| 3 months | +37.68% | ||
| 6 months | +62.66% | ||
| Current year | +50.30% |
1 week
11 000.00
15 400.00
1 month
10 820.0022 450.00
Current year
8 000.0026 500.00
1 year
5 900.0026 500.00
3 years
5 900.0026 500.00
5 years
5 900.0026 500.00
10 years
5 900.0026 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hak-Jong Lee
CEO | Chief Executive Officer | - | - |
IMGT Corp Ltd is a Korea-based company principally engaged in the drug delivery system development and sale business. The Company focus on researching and developing of ultrasound-guided therapy technology which utilizes ultrasound and nanoparticle technology. The Company provides IMGT-LPS, IMGT-EMB and IMGT-TSD technologies. IMGT-LPS technology injects ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances into body and releases drugs by irradiating ultrasound to the target area. IMGT-EMB is a nanoparticle for chemoembolization of liver cancer and can be injected into cancer area in form of emulsion. IMGT-TSD is a targeted sonodynamic therapy induces immune boosting mechanism by applying ultrasonic stimulation to the cancer area. In addition, the Company engages in the non-invasive treatment devices IMGT-FUS which using focused ultrasound technology.
| 1st Jan change | Capi. | |
|---|---|---|
| +50.30% | 41.98M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- A456570 Stock